
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is well-positioned within the growing and rapidly evolving field of personalized cancer therapies. The recent acquisition by Tempus AI for a significant premium to the market price further solidifies the potential for the company and its technologies. With a strong and diverse product portfolio, as well as a growing revenue stream, Personalis has the potential for significant long-term growth and success.
Bears say
Personalis is facing several challenges that could hamper its growth potential, including delays in building out its clinical diagnostics program, low gross and negative operating margins, and significant cash burn, which may result in a discounted valuation for the stock. Additionally, the company's acquisition by Tempus AI (TEM) may not provide significant upside, and there is a possibility for further volatility or softness in its biopharma business, as well as declining demand for personalized cancer vaccines. In a bear case scenario, the company's stock price could reach $6.00 per share.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares